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mutations had been identified in more than 20 distinct
FTDP-17 kindreds by the end of 1998 (Figure 1). More-
over, reports of new tau gene mutations pathogenic
for FTDP-17 syndromes in additional kindreds with this
hereditary tauopathy continue to appear with surprising
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frequency. Indeed, it is highly likely that other distinctlySchool of Medicine
different tau gene mutations will continue to be discov-Philadelphia, Pennsylvania 19104
ered and published for some time into the future as
more kindreds with previously unrecognized FTDP-17
syndromes are characterized and increasing attentionProminent filamentous tau inclusions are increasingly
is focused on the relationship of different FTDP-17 geno-recognized as the hallmark neuropathology of a growing
types to the heterogeneous phenotypic manifestationsfamily of neurodegenerative diseases collectively known
of these hereditary neurodegenerative tauopathies (Hongas tauopathies. The discovery of autosomal dominant
et al., 1999). Although hereditary FTDP-17 syndromespathogenic tau gene mutations in frontotemporal de-
are the genetically determined counterparts of seem-mentia with parkinsonism linked to chromosome 17
ingly sporadic FTDs, it must be acknowledged that the(FTDP-17) has led to the rapid emergence of new in-
role of genetic versus epigenetic factors in the onsetsights into mechanisms underlying FTDP-17, Alzhei-
and progression of this group of tauopathies remainsmer's disease (AD), and related tauopathies, as well as
largely unexplored. This notwithstanding, the remark-fresh opportunities to develop transgenic (TG) mouse
able discovery of pathogenic tau gene mutations inmodels of these disorders. Recent efforts to generate
FTDP-17 families provides unequivocal support for theTG mice that recapitulate neurodegenerative tauopathy
hypothesis that defects in the tau gene are sufficient tophenotypes are reviewed, and the design of additional
cause a neurodegenerative disorder.TG mouse models that will hasten discovery of novel
The discovery of tau gene mutations in FTDP-17 kin-and more effective therapies for these disorders is dis-
dreds provides unique opportunities to elucidate thecussed.
disease mechanisms that underlie FTDP-17 as well asFilamentous tau inclusions, accompanied by exten-
related brain disorders characterized by abundant insol-sive neuron loss and gliosis, are the neuropathological
uble intracellular filamentous tau inclusions includinghallmarks of an expanding family of neurodegenerative
AD. Indeed, the tau inclusions in several FTDP-17 syn-diseases that are now collectively known as tauopa-
dromes are remarkably similar to the neurofibrillary tan-thies. Representative examples of this heterogeneous
gles (NFTs) formed by paired helical filaments (PHFs)group of neurodegenerative disorders include AD,
composed of hyperphosphorylated tau (PHFtau) in spo-Down's syndrome (DS), several variants of prion dis-
radic as well as familial AD (Hong et al., 1999). However,eases, progressive supranuclear palsy (PSP), amyotro-
while the filamentous tau tangles in some FTDP-17 syn-phic lateral sclerosis/parkinsonism-dementia complex
dromes occur primarily in neurons, as in the AD brain,of Guam (ALS/PDC), Pick's disease (PiD), corticobasal
aggregated tau filaments are also found in astrocytesdegeneration (CBD), sporadic frontotemporal demen-
and oligodendrocytes in the brains of many FTDP-17tias (FTDs), and familial FTDP-17 syndromes (Goedert
pedigrees (Goedert et al., 1998; Hong et al., 1999). Cur-
et al., 1998; Hong et al., 1999). Although the tau patholo-
rently, it is unclear if and how glial tau tangles in FTDP-
gies in the brains of patients with AD, DS, and several
17 cause neurodegeneration, but similar tau tangles
other tauopathies coexist with additional diagnostic have also been detected in astrocytes and oligoden-
brain lesions (e.g., abundant deposits of Ab in AD and drocytes of several sporadic tauopathies, including
DS), the brains of patients with a number of neurodegen- PSP, CBD, and PiD. Since extensive overlap in clinical
erative tauopathies are characterized almost exclusively and pathological features has been observed between
by prominent tau inclusions. Well-studied examples FTDP-17 syndromes and sporadic tauopathies, an un-
thereof include PiD, CBD, PSP, ALS/PDC, and FTDP- derstanding of how the different tau mutations cause
17 syndromes (Goedert et al., 1998; Hong et al., 1999). FTDP-17 should provide important insights into the
Although defects in the tau gene had been speculated pathogenic mechanisms of sporadic tauopathies.
for some time to cause hereditary tauopathies such as Insight into how tau gene mutations may cause brain
FTDP-17, little or no evidence to substantiate this con- degeneration has come from observations that different
cept had emerged until mid-1998, when Poorkaj et al. intronic and exonic tau gene mutations in FTDP-17 fami-
reported the first pathogenic tau gene mutation in an lies lead to tau aggregation or impair the ability of tau
FTDP-17 kindred. This was followed shortly thereafter to promote microtubule (MT) assembly by altering exon
by a number of reports describing additional mutations (E) 10 splicing or binding to MTs, respectively (Clark et
in other kindreds (Clark et al., 1998; Dumanchin et al., al., 1998; D'Souza et al., 1999; Goedert et al., 1999; Hong
1998; Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998; Hutton et al., 1998). In the adult human
et al., 1998). More than 15 different pathogenic tau gene brain, six tau isoforms are generated by alternative
mRNA splicing of 11 exons in the tau gene (Goedert et
al., 1998; Hong et al., 1999). Alternative splicing of E2 and* To whom correspondence should be addressed (e-mail: vmylee@
mail.med.upenn.edu). E3 of the tau gene generates isoforms with or without a
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Figure 1. Multiple tau Gene Mutations Cause
FTDP-17 by Two Different Mechanisms
The structure of the largest tau isoform is
shown. The striped boxes near the amino ter-
minus represent amino terminal inserts en-
coded by exons 2 and 3, while the black
boxes represent each of the four MT binding
repeats (not to scale). The second MT binding
repeat is encoded for by exon 10. The region
of the tau gene containing exon 10 is enlarged
to better visualize the mutations in exon 10
and at the 59 junction between exon and in-
tron 10. The nucleotide (shaded box) and cor-
responding amino acid sequence of the mu-
tation-containing regions of exon 10 are
shown. Nucleotides that are part of intron 10
are shown in lower case. The dark gray out-
line surrounding a portion of the nucleotide
sequence indicates the region of exon 10 en-
coding the second MT binding repeat. The
positions of the missense mutations that per-
turb tau function are denoted by closed cir-
cles, mutations that alter splicing of exon 10
are marked by closed triangles, and the muta-
tion that alters both tau function and exon 10
splicing is denoted by an asterisk.
29- or 58-amino-acid-long amino-terminal (N) insert (i.e., inclusions could represent a gain of toxic function in-
duced by missense tau mutations leading to the death0N, 1N, and 2N tau isoforms, respectively). Alternative
splicing of E10 gives rise to three tau isoforms with three of affected cells (Goedert et al., 1999).
Several other tauopathies, in particular AD, containMT binding repeats (R) and three tau isoforms with four
MT binding repeats (i.e., 3R and 4R tau isoforms, respec- both NFTs and amyloid plaques. A number of autosomal
dominant mutations in the amyloid precursor proteintively). The recent demonstration that the ratio of 3Rtau
(3R0N, 3R1N, 3R2N) to 4Rtau (4R0N, 4R1N, 4R2N) iso- (APP), presenilin 1 (PS1), and presenilin 2 (PS2) genes
have been identified that increase the production of theforms in the normal brain is z1 suggests that the alterna-
tive splicing of the tau gene is tightly regulated (Hong more amyloidogenic form of the amyloid b (Ab) peptide.
This, in turn, is thought to be a cause of early onsetet al., 1998).
Studies indicate that increased E10 splicing in the familial AD (FAD). In FAD, the formation of tau patholo-
gies is, therefore, most likely a downstream conse-brains of FTDP-17 patients augments expression of
4Rtau proteins, whereas decreased E10 splicing re- quence of FAD mutations. However, the development
of tau lesions could represent a final common pathwayduces the expression of 4Rtau proteins (Clark et al.,
1998; Spillantini et al., 1998; D'Souza et al., 1999). Unlike that leads to the degeneration of neurons in FAD as
well as in sporadic AD and other tauopathies (Figure 2).NFTs in AD, which are comprised of all six tau isoforms
found predominantly in affected neurons, increased E10 Accordingly, tau dysfunction and filamentous tau aggre-
gates must be considered plausible targets for the de-splicing leads to tangles comprised predominantly of
4Rtau, while decreased E10 splicing results in the aggre- velopment of novel and more effective drugs for the
treatment not only of FTDP-17 but also for the treatmentgation predominantly of 3Rtau (Hong et al., 1998;
D'Souza et al., 1999). Significantly, 4Rtau tangles are of AD, FTDs, and other tauopathies (Goedert et al., 1998;
Hong et al., 1999). For these reasons, transgenic (TG)not only found in neurons, they are also present in
astrocytes and oligodendrocytes of affected FTDP-17 mouse models of FTDP-17 tauopathies also may serve
as informative models for research into the role tau pa-kindreds. Similar aggregation of insoluble 4Rtau or
3Rtau isoforms as cytoplasmic inclusions in the same thologies play in the onset/progression of FTDP-17, AD,
and related tauopathies.cell types are also found in sporadic FTDs such as CBD
and PSP or PiD, respectively, suggesting that the dereg- Early efforts to produce animal models with tau pa-
thologies were based on the expectation that TG miceulation of E10 splicing by unknown pathogenic mecha-
nisms may be responsible for sporadic FTDs. that developed amyloid plaques would be good models
of AD. The overexpression of APP with FAD mutationsThe identification of autosomal dominant tau gene
mutations provides unequivocal evidence that tau ab- at very high levels produced TG mice that recapitulated
some of the neuropathological features of human AD,normalities do not require the presence of other brain
lesions (e.g., amyloid plaques) to induce a neurodegen- including the formation of diffuse and neuritic Ab
plaques, but tau positive NFTs were never observederative disorder. Recent studies have suggested that
some of the missense tau gene mutations might cause (Games et al., 1995; Hsiao et al., 1996). Significantly,
neuron loss was not detected in these APP TG miceFTDP-17 by impairing the ability of tau to bind MTs
(Hong et al., 1998), which could destabilize MTs, disrupt even when they aged (Irizarry et al., 1997). Other TG
mouse models, such as those that overexpress FAD-axonal transport, and lead to the dying back of axons
culminating in the death of affected neurons. Alterna- linked PS1 mutations alone or FAD-linked PS1 and APP
mutations together, also did not develop tau pathology,tively, the formation of intracytoplasmic filamentous tau
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Figure 2. Current View on the Central Role of
Tau Dysfunction in the Pathogenesis of Neu-
rodegenerative Tauopathies, Including AD
Genetic factors such as mutations in the tau,
amyloid precursor protein (APP), Presenilin 1
(PS1) and 2 (PS2) genes, and other yet to be
identified susceptibilities, as well as environ-
mental factors, may initiate pathogenic pro-
cesses through different mechanisms, all of
which may converge to induce the dysfunc-
tion and aggregation of tau leading to the
degeneration of affected brain regions. DeP-
Tau and P-Tau refer to dephosphorylated
and hyperphosphorylated tau, respectively.
although the double TG mouse lines did show acceler- ventral roots, a loss of MTs as well as reduced fast
axonal transport in residual ventral root axons, extensiveated accumulation of Ab plaques suggesting a syner-
gistic effect of these two mutant genes (Price and Si- spinal cord gliosis, and motor weakness. Thus, the over-
expression of a single tau isoform can lead to the devel-sodia, 1998). Taken together, the generation of Ab
plaques in different TG mouse using FAD transgenes is opment of filamentous tau-rich inclusions and neurode-
generation.insufficient alone to induce tau pathologies and cause
neurons to die. It is important to note that our current tau TG mice
recapitulate some, but not all, aspects of prototypicalEfforts to produce animal models of tau pathologies
by directly overexpressing the tau gene have been tauopathies. For example, previous studies have shown
that NF proteins are only found in NFTs at late stageslimited, but further efforts will be facilitated by the dis-
covery of the FTDP-17 tau gene mutations. Initial reports of the disease in AD patients. Thus, it will be important to
generate TG mice that develop filamentous tau tanglesdescribed TG mouse lines overexpressing 4R2N or
3R0N human tau using cDNAs driven by Thy-1 and without any associated NF proteins early on in the dis-
ease pathogenesis. Our initial rationale for overexpress-by 3-hydroxy-3methyglutaryl coenzyme A reductase
promoters, respectively. Both of these lines developed ing the smallest 3Rtau in mice is based on the notion
that rodents only express 4Rtau and they never developªpretangleº tau pathology but no filamentous tau inclu-
sions (Goetz et al., 1995; Brion et al., 1999). The lack of tau pathologies spontaneously as they age. Thus, by
overexpressing the missing 3Rtau isoform, we thoughttau filament formation in the TG models may be due to
the low level of transgene expression in these mice. we might be able to induce NFT formation. However,
these mice did not develop tangles identical to NFTs,Notably, intraneuronal injections of tau cDNA containing
plasmids followed by the massive overexpression of but they did develop filamentous tau inclusions that
were comprised almost exclusively of 3Rtau, much like4R2N human tau have been shown to lead to the forma-
tion of PHFtau-like filamentous inclusions and the de- those found in PiD and the FTDP-17 kindred with the
D280K tau mutation.generation of some affected neurons in the lamprey
central nervous system (Hall et al., 1997). Encouraged Other TG mice must be generated that exploit the
FTDP-17 tau gene mutations, and these mice shouldby these results, we recently produced TG mouse lines
that express 5- to 15-fold higher levels of wild-type (WT) provide important insights into how the mutations cause
loses of normal tau function, toxic gains of function, orhuman 3R0N tau than endogenous mouse tau. These
mice developed argyrophilic (silver positive) inclusions both. Further, it also is critical to develop tau TG mice
using glial- as well as neuron-specific promoters toformed by aggregated 10±20 nm filaments composed
of tau and neurofilament (NF) proteins (Ishihara et al., drive transgene expression, since oligodendrocytes and
astrocytes as well as neurons accumulate tau tangles1999 [this issue of Neuron]). However, these filaments
did not exhibit the ultrastructural features of PHFs in in many tauopathies. Thus, by developing tau TG mouse
models that acquire glial tau pathology, it will be possi-classic AD NFTs, although tau protein isolated from
brain and spinal cord of these mice became progres- ble to investigate the contribution of glial tangles in
neurodegenerative tauopathies. Additionally, since allsively insoluble and more phosphorylated with advanc-
ing age. Further, the accumulation of these tau-rich le- six tau isoforms are present in the adult human brain
and since many of the FTDP-17 tau gene mutationssions in the tau TG mice is transgene dose dependent
and age dependent. Most significantly, these TG mice affect E10 splicing through multiple mechanisms, it also
is highly desirable to develop TG animals with and with-developed a phenotype more similar to that seen in
tauopathies such as FTDP-17, PSP, and ALS/PDC, out E10 splice mutations using the P1-derived artificial
chromosome (PAC) containing the entire tau gene. Therather than that seen in AD, since the tau pathologies
in these TG mice were more abundant in spinal cord WT and mutant tau PAC animals will be invaluable in
studies of the alternative splicing of the tau gene andand brain stem. The spinal cord inclusions were associ-
ated with axonal degeneration in related spinal cord how altered splicing results in tau pathologies as well
Neuron
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as age-dependent neurodegeneration. Additional and
perhaps more authentic TG mouse models of tauopa-
thies could be developed by crossing PAC mice harbor-
ing intronic or exonic FTDP-17 tau gene mutations with
tau gene knockout mice to generate ªhumanizedº tau
TG lines.
Finally, it would be desirable to produce model sys-
tems that more accurately recapitulate the hallmark pa-
thology of AD by crossing the various tau TG mice with
TG mouse models of AD Ab amyloidosis. Accordingly,
by producing TG mouse models designed to exploit
the new insights into the pathobiology of tauopathies
discussed here, it should be possible to make rapid
progress in elucidating how and why glial and neuronal
tau pathologies lead to the onset and progression of
sporadic and hereditary neurodegenerative diseases
characterized by prominent filamentous tau inclusions.
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